- Home
- GGR vs QNCX Comparison
GGR vs QNCX Comparison
Compare GGR & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGR
- QNCX
- Stock Information
- Founded
- GGR 2011
- QNCX 2012
- Country
- GGR Taiwan
- QNCX United States
- Employees
- GGR N/A
- QNCX N/A
- Industry
- GGR Auto Manufacturing
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GGR Consumer Discretionary
- QNCX Health Care
- Exchange
- GGR Nasdaq
- QNCX Nasdaq
- Market Cap
- GGR 101.1M
- QNCX 85.9M
- IPO Year
- GGR N/A
- QNCX 2019
- Fundamental
- Price
- GGR $0.32
- QNCX $1.60
- Analyst Decision
- GGR Hold
- QNCX Strong Buy
- Analyst Count
- GGR 2
- QNCX 6
- Target Price
- GGR $0.50
- QNCX $8.00
- AVG Volume (30 Days)
- GGR 216.4K
- QNCX 124.9K
- Earning Date
- GGR 11-13-2025
- QNCX 11-12-2025
- Dividend Yield
- GGR N/A
- QNCX N/A
- EPS Growth
- GGR N/A
- QNCX N/A
- EPS
- GGR N/A
- QNCX N/A
- Revenue
- GGR $289,420,000.00
- QNCX N/A
- Revenue This Year
- GGR N/A
- QNCX N/A
- Revenue Next Year
- GGR $5.00
- QNCX N/A
- P/E Ratio
- GGR N/A
- QNCX N/A
- Revenue Growth
- GGR N/A
- QNCX N/A
- 52 Week Low
- GGR $0.19
- QNCX $0.69
- 52 Week High
- GGR $1.03
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- GGR 37.65
- QNCX 47.89
- Support Level
- GGR $0.34
- QNCX $1.56
- Resistance Level
- GGR $0.36
- QNCX $1.65
- Average True Range (ATR)
- GGR 0.02
- QNCX 0.07
- MACD
- GGR -0.00
- QNCX 0.00
- Stochastic Oscillator
- GGR 11.17
- QNCX 64.65
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.